Literature DB >> 20538860

Immediate-early expression of a recombinant antigen by modified vaccinia virus ankara breaks the immunodominance of strong vector-specific B8R antigen in acute and memory CD8 T-cell responses.

Karen Baur1, Kay Brinkmann, Marc Schweneker, Juliane Pätzold, Christine Meisinger-Henschel, Judith Hermann, Robin Steigerwald, Paul Chaplin, Mark Suter, Jürgen Hausmann.   

Abstract

Efficient T-cell responses against recombinant antigens expressed by vaccinia virus vectors require expression of these antigens in the early phase of the virus replication cycle. The kinetics of recombinant gene expression in poxviruses are largely determined by the promoter chosen. We used the highly attenuated modified vaccinia virus Ankara (MVA) to determine the role of promoters in the induction of CD8 T-cell responses. We constructed MVA recombinants expressing either enhanced green fluorescent protein (EGFP) or chicken ovalbumin (OVA), each under the control of a hybrid early-late promoter (pHyb) containing five copies of a strong early element or the well-known early-late p7.5 or pS promoter for comparison. In primary or cultured cells, EGFP expression under the control of pHyb was detected within 30 min, as an immediate-early protein, and remained higher over the first 6 h of infection than p7.5- or pS-driven EGFP expression. Repeated immunizations of mice with recombinant MVA expressing OVA under the control of the pHyb promoter led to superior acute and memory CD8 T-cell responses compared to those to p7.5- and pS-driven OVA. Moreover, OVA expressed under the control of pHyb replaced the MVA-derived B8R protein as the immunodominant CD8 T-cell antigen after three or more immunizations. This is the first demonstration of an immediate-early neoantigen expressed by a poxviral vector resulting in superior induction of neoantigen-specific CD8 T-cell responses.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20538860      PMCID: PMC2919044          DOI: 10.1128/JVI.00604-10

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  52 in total

1.  Cloning and characterization of the gene encoding the major protein of the A-type inclusion body of cowpox virus.

Authors:  S Funahashi; T Sato; H Shida
Journal:  J Gen Virol       Date:  1988-01       Impact factor: 3.891

Review 2.  Prime-boost vectored malaria vaccines: progress and prospects.

Authors:  Adrian V S Hill; Arturo Reyes-Sandoval; Geraldine O'Hara; Katie Ewer; Alison Lawrie; Anna Goodman; Alfredo Nicosia; Antonella Folgori; Stefano Colloca; Riccardo Cortese; Sarah C Gilbert; Simon J Draper
Journal:  Hum Vaccin       Date:  2010-01-18

3.  [MVA vaccination against smallpox: clinical tests with an attenuated live vaccinia virus strain (MVA) (author's transl)].

Authors:  H Stickl; V Hochstein-Mintzel; A Mayr; H C Huber; H Schäfer; A Holzner
Journal:  Dtsch Med Wochenschr       Date:  1974-11-22       Impact factor: 0.628

4.  High-frequency homologous recombination in vaccinia virus DNA.

Authors:  L A Ball
Journal:  J Virol       Date:  1987-06       Impact factor: 5.103

5.  In vitro mutagenesis of the promoter region for a vaccinia virus gene: evidence for tandem early and late regulatory signals.

Authors:  M A Cochran; C Puckett; B Moss
Journal:  J Virol       Date:  1985-04       Impact factor: 5.103

6.  Evolution of the T cell repertoire during primary, memory, and recall responses to viral infection.

Authors:  J N Blattman; D J Sourdive; K Murali-Krishna; R Ahmed; J D Altman
Journal:  J Immunol       Date:  2000-12-01       Impact factor: 5.422

7.  Enhanced CD8+ T cell immune responses and protection elicited against Plasmodium berghei malaria by prime boost immunization regimens using a novel attenuated fowlpox virus.

Authors:  Richard J Anderson; Carolyn M Hannan; Sarah C Gilbert; Stephen M Laidlaw; Eric G Sheu; Simone Korten; Robert Sinden; Geoffrey A Butcher; Michael A Skinner; Adrian V S Hill
Journal:  J Immunol       Date:  2004-03-01       Impact factor: 5.422

Review 8.  Vaccinia virus transcription.

Authors:  Steven S Broyles
Journal:  J Gen Virol       Date:  2003-09       Impact factor: 3.891

9.  Temporal regulation of influenza hemagglutinin expression in vaccinia virus recombinants and effects on the immune response.

Authors:  B E Coupar; M E Andrew; G W Both; D B Boyle
Journal:  Eur J Immunol       Date:  1986-12       Impact factor: 5.532

Review 10.  Vaccinia vectors as candidate vaccines: the development of modified vaccinia virus Ankara for antigen delivery.

Authors:  Gerd Sutter; Caroline Staib
Journal:  Curr Drug Targets Infect Disord       Date:  2003-09
View more
  27 in total

Review 1.  Enhancing poxvirus vectors vaccine immunogenicity.

Authors:  Juan García-Arriaza; Mariano Esteban
Journal:  Hum Vaccin Immunother       Date:  2014       Impact factor: 3.452

2.  Interference with SAMHD1 Restores Late Gene Expression of Modified Vaccinia Virus Ankara in Human Dendritic Cells and Abrogates Type I Interferon Expression.

Authors:  Katja Sliva; Judith Martin; Christine von Rhein; Tobias Herrmann; Anastasia Weyrich; Masako Toda; Barbara S Schnierle
Journal:  J Virol       Date:  2019-10-29       Impact factor: 5.103

Review 3.  CD8+ T cells in Trypanosoma cruzi infection.

Authors:  Rick L Tarleton
Journal:  Semin Immunopathol       Date:  2015-04-29       Impact factor: 9.623

4.  Recombinant Modified Vaccinia Virus Ankara Generating Ebola Virus-Like Particles.

Authors:  Marc Schweneker; Andrea S Laimbacher; Gert Zimmer; Susanne Wagner; Elisabeth M Schraner; Michael Wolferstätter; Marieken Klingenberg; Ulrike Dirmeier; Robin Steigerwald; Henning Lauterbach; Hubertus Hochrein; Paul Chaplin; Mark Suter; Jürgen Hausmann
Journal:  J Virol       Date:  2017-05-12       Impact factor: 5.103

5.  Recombinant modified vaccinia virus Ankara generating excess early double-stranded RNA transiently activates protein kinase R and triggers enhanced innate immune responses.

Authors:  Michael Wolferstätter; Marc Schweneker; Michaela Späth; Susanne Lukassen; Marieken Klingenberg; Kay Brinkmann; Ursula Wielert; Henning Lauterbach; Hubertus Hochrein; Paul Chaplin; Mark Suter; Jürgen Hausmann
Journal:  J Virol       Date:  2014-10-08       Impact factor: 5.103

6.  Expression and cellular immunogenicity of a transgenic antigen driven by endogenous poxviral early promoters at their authentic loci in MVA.

Authors:  Toritse Orubu; Naif Khalaf Alharbi; Teresa Lambe; Sarah C Gilbert; Matthew G Cottingham
Journal:  PLoS One       Date:  2012-06-27       Impact factor: 3.240

Review 7.  The evolution of poxvirus vaccines.

Authors:  Lucas Sánchez-Sampedro; Beatriz Perdiguero; Ernesto Mejías-Pérez; Juan García-Arriaza; Mauro Di Pilato; Mariano Esteban
Journal:  Viruses       Date:  2015-04-07       Impact factor: 5.048

8.  A novel naturally occurring tandem promoter in modified vaccinia virus ankara drives very early gene expression and potent immune responses.

Authors:  Sonia T Wennier; Kay Brinkmann; Charlotte Steinhäußer; Nicole Mayländer; Claudia Mnich; Ursula Wielert; Ulrike Dirmeier; Jürgen Hausmann; Paul Chaplin; Robin Steigerwald
Journal:  PLoS One       Date:  2013-08-12       Impact factor: 3.240

9.  Genetic Adjuvantation of Recombinant MVA with CD40L Potentiates CD8 T Cell Mediated Immunity.

Authors:  Henning Lauterbach; Juliane Pätzold; Ronny Kassub; Barbara Bathke; Kay Brinkmann; Paul Chaplin; Mark Suter; Hubertus Hochrein
Journal:  Front Immunol       Date:  2013-08-27       Impact factor: 7.561

10.  A Higher Activation Threshold of Memory CD8+ T Cells Has a Fitness Cost That Is Modified by TCR Affinity during Tuberculosis.

Authors:  Stephen M Carpenter; Cláudio Nunes-Alves; Matthew G Booty; Sing Sing Way; Samuel M Behar
Journal:  PLoS Pathog       Date:  2016-01-08       Impact factor: 6.823

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.